All In Biotech

Drug Trial Radar · NCT02040792

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2B, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

355

Actual

Start

May 2014

Primary completion

Jul 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Mylan Inc.Industry
Sponsor type
Industry
Collaborators
Theravance Biopharma
First posted
Jan 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.

Conditions

  • COPD

Interventions

  • TD-4208Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second)Time frame: Baseline to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Upstate Pharmaceutical Research

    Greenville, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.